Aardvark Therapeutics Inc (AARD) Stock Price, Quote & News

Company Profile

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 858 225 7696

Website: aardvarktherapeutics.com

Address:

4370 La Jolla Village Drive, Suite 1050, San Diego, United States

AnomalyDetective Jul. 1 at 12:12 PM

💥 $AARD +16.0% the 3rd of 4 MDA Breakout picks of the week to gain over 10% through Tuesday for members in this short trading week. Four new Week 28 MDA breakout selections go out early this week for members after the close today: https://seekingalpha.com/mp/1201-value-momentum-breakouts Markets are closed Friday in observance of US Independence Day 🇺🇸 💥 Up to 12,600 daily breakout picks are available annually at vmbreakouts.com @vmbreakouts many prior free selections available here: http://top.vmbreakouts.com

0 · Reply

jumanah1212 Jun. 25 at 9:34 PM

$AARD tomorrow 💸💸💸

0 · Reply

jumanah1212 Jun. 24 at 11:48 PM

$AARD 💸💸🚀🚀🚀🚀

0 · Reply

jumanah1212 Jun. 24 at 9:01 PM

$AARD 🚀🚀🚀🚀💸💸💸 I wish you profits

0 · Reply

jumanah1212 Jun. 24 at 8:28 PM

$AARD 6.66 -12.00💰🚀🚀🚀

0 · Reply

focafoca99 Jun. 19 at 3:21 PM

$AARD has paused its Phase 3 HERO trial amid a 56% share drop and an investor fraud investigation.

0 · Reply

ScamBuster0 Jun. 15 at 6:50 PM

$AARD Retention bonuses? Cash, not stock options. Why is precious cash being used on people who screwed up the execution of the clinical development of ARD-101? Or was the fired for cause former COO the scapegoat for all the screw-ups. How was this allowed to happen to not even understand the pharmacokinetics of the drug being clinically developed? Where was the CEO? Where was the Board to allow this crap to continue? In my opinion, all of them (CEO, former COO, CMO and CFO, along with all the Board members) need to be sued for shareholder fraud. The Board didn't do their job. The CEO didn't do his job. Incompetitence reigned supreme. The CFO was a real estate guy, how is that relevant to a pharma company? The CEO had no formal management training, just another medical diety.

0 · Reply

focafoca99 May. 21 at 1:29 PM

$AARD faces investor scrutiny after pausing its HERO trial amid a securities law investigation.

0 · Reply

ScamBuster0 May. 16 at 7:33 AM

$AARD All I can say is what MORON decided to run a volunteer safety study dosing 3.2 grams of a drug (1600 mg BID) daily? Didn't anyone do a mass balance study to understand the systemic drug concentration? That's standard PK. And wasn't there any intelligent tox work to understand what is the sign of too high a dose (like the cardiac effect described that sounds an awful like lidocaine, a safe drug that avoids too high a systemic dose). The standard tox saying is "the dose makes the poison." Even aspirin at too high a dose is toxic. Don't take 3.2 grams of aspirin. The Board needs to step up and fire everyone and bring in folks who are not incompetent morons. Lee needs to go.

1 · Reply

AStrokeOfLuck May. 15 at 6:46 PM

$AARD

0 · Reply

Aardvark Therapeutics Proxy statement: Proxy filing

Jun 25, 2026, 9:00 AM EDT - 6 days ago

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS

2026-05-15T20:00:16.000Z - 6 weeks ago

Aardvark Therapeutics downgraded to Underperform from Buy at BofA

NBIX RYTM

2026-05-15T15:16:12.000Z - 6 weeks ago

Aardvark Therapeutics price target lowered to $7 from $8 at B. Riley

2026-05-15T14:43:58.000Z - 6 weeks ago

Aardvark Therapeutics Inc trading halted, volatility trading pause

2026-05-15T14:36:56.000Z - 6 weeks ago

Aardvark Therapeutics Inc trading resumes

2026-05-15T13:30:50.000Z - 6 weeks ago

Aardvark Therapeutics downgraded to Neutral from Buy at BTIG

2026-05-15T08:45:48.000Z - 6 weeks ago

Aardvark downgraded to Underweight from Equal Weight at Morgan Stanley

2026-05-14T22:08:33.000Z - 6 weeks ago

Aardvark Therapeutics announces FDA clinical hold on ARD-101

May 14, 2026, 4:53 PM EDT - 6 weeks ago

FDA places full clinical hold on Aardvark's drug for extreme hunger in Prader-Willi syndrome

May 14, 2026, 4:01 PM EDT - 6 weeks ago

Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold

2026-05-10T14:36:28.000Z - 7 weeks ago

Aardvark Therapeutics price target lowered to $18 from $20 at BofA

2026-05-07T19:19:23.000Z - 7 weeks ago

Aardvark Therapeutics reports Q1 EPS (99c), consensus (91c)

May 7, 2026, 8:00 AM EDT - 7 weeks ago

Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

May 7, 2026, 7:00 AM EDT - 7 weeks ago

Aardvark Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 7 weeks ago

Aardvark Therapeutics Earnings release: Q1 2026

2026-03-24T12:42:34.000Z - 3 months ago

Aardvark Therapeutics price target lowered to $8 from $32 at B. Riley

2026-03-23T21:15:11.000Z - 3 months ago

Aardvark Therapeutics files $400M mixed securities shelf

2026-03-23T20:16:52.000Z - 3 months ago

Aardvark Therapeutics reports Q4 EPS (81c), consensus (83c)

Mar 23, 2026, 4:05 PM EDT - 3 months ago

Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 23, 2026, 4:00 PM EDT - 3 months ago

Aardvark Therapeutics Annual report: Q4 2025

Mar 23, 2026, 4:00 PM EDT - 3 months ago

Aardvark Therapeutics Earnings release: Q4 2025

Mar 23, 2026, 8:00 AM EDT - 3 months ago

Aardvark Therapeutics Registration statement: Registration filing

Mar 11, 2026, 9:00 AM EDT - 4 months ago

Aardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm

2026-03-02T14:01:55.000Z - 4 months ago

Aardvark Therapeutics price target lowered to $45 from $50 at Cantor Fitzgerald

2026-03-02T12:51:55.000Z - 4 months ago

Aardvark Therapeutics price target lowered to $9 from $26 at BTIG

2026-03-02T12:43:32.000Z - 4 months ago

Aardvark Therapeutics price target lowered to $21 from $35 at Oppenheimer

2026-03-02T12:28:45.000Z - 4 months ago

Why Is Aardvark Therapeutics Stock (AARD) Down Today?

Feb 27, 2026, 4:05 PM EST - 4 months ago

Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome

Feb 13, 2026, 8:00 AM EST - 4 months ago

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 12, 2026, 8:00 AM EST - 4 months ago

Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer

Feb 12, 2026, 8:00 AM EST - 4 months ago

Aardvark Therapeutics Announces Leadership Appointments

Feb 10, 2026, 8:00 AM EST - 5 months ago

Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome

Dec 10, 2025, 4:05 PM EST - 7 months ago

Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome

Dec 4, 2025, 11:15 AM EST - 7 months ago

Aardvark Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 8:00 AM EST - 7 months ago

Aardvark Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 4:05 PM EST - 7 months ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in December

Nov 24, 2025, 3:00 PM EST - 7 months ago

Aardvark Therapeutics Transcript: TD Cowen Treatment Advancements in Obesity and Related Disorders Summit

Nov 13, 2025, 4:05 PM EST - 8 months ago

Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Nov 13, 2025, 4:00 PM EST - 8 months ago

Aardvark Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 4:00 PM EST - 8 months ago

Aardvark Therapeutics Earnings release: Q3 2025

Nov 11, 2025, 4:40 PM EST - 8 months ago

Aardvark Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 4:05 PM EST - 8 months ago

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Nov 5, 2025, 5:00 PM EST - 8 months ago

Aardvark Therapeutics Transcript: Study Update

Nov 5, 2025, 5:00 PM EST - 8 months ago

Aardvark Therapeutics Press release: Study Update

Nov 4, 2025, 12:00 PM EST - 8 months ago

Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025

Nov 3, 2025, 5:55 PM EST - 8 months ago

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Nov 3, 2025, 8:00 AM EST - 8 months ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in November

Oct 22, 2025, 8:00 AM EDT - 9 months ago

Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek

Oct 8, 2025, 8:00 AM EDT - 9 months ago

Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome

Sep 30, 2025, 9:00 AM EDT - 9 months ago

Aardvark Therapeutics Transcript: Stifel Virtual Cardiometabolic Forum

Sep 23, 2025, 4:05 PM EDT - 10 months ago

Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Sep 8, 2025, 7:00 AM EDT - 10 months ago

Aardvark Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 11:30 AM EDT - 10 months ago

Aardvark Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 7:00 AM EDT - 10 months ago

Aardvark Therapeutics Slides: Corporate Presentation

Aug 27, 2025, 4:10 PM EDT - 10 months ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in September

Aug 13, 2025, 4:10 PM EDT - 11 months ago

Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Aug 12, 2025, 6:00 PM EDT - 11 months ago

Aardvark Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 6:00 PM EDT - 11 months ago

Aardvark Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy

Jul 18, 2025, 8:00 AM EDT - 1 year ago

Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

Jun 24, 2025, 8:00 AM EDT - 1 year ago

Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference

May 21, 2025, 2:35 PM EDT - 1 year ago

Aardvark Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 3:30 PM EDT - 1 year ago

Aardvark Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 19, 2025, 4:10 PM EDT - 1 year ago

Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

May 15, 2025, 12:35 PM EDT - 1 year ago

Aardvark Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 14, 2025, 4:10 PM EDT - 1 year ago

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 7, 2025, 4:05 PM EDT - 1 year ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

Mar 31, 2025, 4:10 PM EDT - 1 year ago

Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

Feb 12, 2025, 10:38 PM EST - 1 year ago

Aardvark Therapeutics Announces Pricing of Initial Public Offering

AnomalyDetective Jul. 1 at 12:12 PM

0 · Reply

jumanah1212 Jun. 25 at 9:34 PM

$AARD tomorrow 💸💸💸

0 · Reply

jumanah1212 Jun. 24 at 11:48 PM

$AARD 💸💸🚀🚀🚀🚀

0 · Reply

jumanah1212 Jun. 24 at 9:01 PM

$AARD 🚀🚀🚀🚀💸💸💸 I wish you profits

0 · Reply

jumanah1212 Jun. 24 at 8:28 PM

$AARD 6.66 -12.00💰🚀🚀🚀

0 · Reply

focafoca99 Jun. 19 at 3:21 PM

$AARD has paused its Phase 3 HERO trial amid a 56% share drop and an investor fraud investigation.

0 · Reply

ScamBuster0 Jun. 15 at 6:50 PM

0 · Reply

focafoca99 May. 21 at 1:29 PM

$AARD faces investor scrutiny after pausing its HERO trial amid a securities law investigation.

0 · Reply

ScamBuster0 May. 16 at 7:33 AM

1 · Reply

AStrokeOfLuck May. 15 at 6:46 PM

$AARD

0 · Reply

StocktwitsNews May. 15 at 5:24 PM

AARD Stock Crashes 34% – Here’s Why This Analyst Finds It ‘Hard To Lean Into’ Aardvark At This Stage $AARD https://stocktwits.com/news/equity/markets/aard-stock-crashes-brokerages-downgrade-aardvark/cZXm52iRekd

0 · Reply

diggs24 May. 15 at 1:38 PM

$AARD halted

0 · Reply

briefingcom May. 15 at 12:31 PM

$AARD: Aardvark Therapeutics (-33.2%) announces the U.S. Food and Drug Administration has placed a full clinical hold on its investigational new drug application for ARD-101 related to the Company’s previously announced voluntary pause https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260514160540AARD&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

0 · Reply

OpenOutcrier May. 15 at 12:21 PM

$AARD (-37.0% pre) FDA places clinical hold on Aardvark Therapeutics ARD-101 drug trials https://ooc.bz/l/102448

0 · Reply

Xxxxcccemre May. 15 at 11:43 AM

$AARD buyer under 3$ around about at cash position

0 · Reply

mikesterz7 May. 15 at 2:19 AM

$AARD Aardvark Therapeutics said the FDA’s full clinical hold applies to the ongoing late-stage HERO trial for hyperphagia in PWS patients and the associated open-label extension (OLE) study.

0 · Reply

StocktwitsNews May. 14 at 11:07 PM

AARD Stock Plummets After Hours As Cardiac Safety Concerns Trigger FDA Hold On Late-stage Program $AARD $VTI $IWM https://stocktwits.com/news/equity/markets/aard-stock-plummets-after-hours-as-cardiac-safety-concerns-trigger-fda-hold-on-late-stage-program/cZXSEPUReSj

0 · Reply

notreload_ai May. 14 at 10:00 PM

FDA halted $AARD hunger drug trials for safety issues in PWS; studies stop, stock drops 17%, company talks with FDA. https://notreload.xyz/xy/fda-clinical-hold-on-aardvark-ard-101-for-prader-willi/

0 · Reply

Blackrabbit9 May. 13 at 6:39 PM

$AARD

0 · Reply

DonCorleone77 May. 10 at 3:40 PM

$AARD Aardvark Therapeutics price target lowered to $18 from $20 at BofA BofA lowered the firm's price target on Aardvark Therapeutics to $18 from $20 and keeps a Buy rating on the shares. The firm updated the company's model post the Q1 report.

0 · Reply

focafoca99 May. 7 at 1:55 PM

$AARD released its Q1 2026 earnings and business update.

0 · Reply

BillionerOfKing May. 1 at 4:25 AM

$AARD Current Stock Price: $5.43 Contracts to trade: $5.0 AARD May 15 2026 Call Entry: $1.08 Exit: $1.65 ROI: 53% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Market Cap	113.01M
Revenue (ttm)	0.00
Net Income (ttm)	-57.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	228,300
Avg Vol	190,332
Day's Range	N/A - N/A
Shares Out	21.82M
Stochastic %K	99%
Beta	4.50
Analysts	Sell
Price Target	$11.75